DOCSLIB.ORG

Cryptosporidium Cystoisospora Belli Cyclospora Cayetanensis © by Author

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cryptosporidium Cystoisospora Belli Cyclospora Cayetanensis © by Author Coccidians Cryptosporidium Cystoisospora belli Cyclospora cayetanensis © by author ESCMID Online Lecture Library © by author ESCMID Online Lecture Library © by author ESCMID Online Lecture Library © by author ESCMID Online Lecture Library © by author ESCMID Online Lecture Library Diagnostic techniques Cryptosporidium Cyclospora cayetanensis Cystoisospora belli sporulation In host weeks days seize 2-5 μm 5-8 μm flask JKJ no uptake no uptake no uptake Acid fast + ©+ by author + Autofluorescence - + + ESCMID Online Lecture Library © by author ESCMID Online Lecture Library Auto fluorescence • Prepare direct smear or a smear from Ridley sediment in saline (not JKJ) • Screen smear with fluorescence microscope with excitation filter 340-380 nm (20x10; details 40x10) • oöcyst wall: blue/white© by fluorescent author • Also for SAF preserved samples ESCMID Online Lecture Library Treatment Cyclospora / Cystoisospora belli • Co-trimoxazol – 2dd TMP 160 mg SMX 800 mg x 7-10 d – Children – 2dd TMP 5 mg/kg SMX 25 mg/kg x 7-10 d © by author ESCMID Online Lecture Library Cryptosporidium HIV / AIDS Waterborne outbreaks © by author ESCMID Online Lecture Library Clinical presentation Immunocompetent individuals: • Self-limiting diarrhea • Vomiting • Nausea, decreased appetite, weight loss, flatulence • Abdominal pain and cramps. Immunocompromised individuals: CD4 Tcell-count <200 mm3 © by author • persistent diarrheal infection >30 days • severe illness. ESCMID Online Lecture Library Clinical presentation / species - Cryptosporidium parvum - Cryptosporidium hominis - other species (eg C felis) non pathogenic 4 humans © by author ESCMID Online Lecture Library Treatment - Metronidazole / Tinidazole - Secnidazole - Clioquinol - Albendazol - Paromomycine - Cotrimoxazole - Doxycycline - In different dosages /© combinations by author ESCMID Online Lecture Library Nitazoxanide - Alinia / Annita. FDA approved 2004 - > 11 jaar 2dd 500 mg 3 dagen - Nitrothiazolyl- salicylamide derivaat - 2-acetyloxy-N-(5-nitro-2-thiazolyl)benzamide - Metabolized to tizoxamide - Pyruvaat:ferredoxine oxidoreductase (PFOR) - Anaerobe energie metabolisme© by author (Giardia) ESCMID Online Lecture Library Placebo controlled trials Nitazoxanide: 3-day course of nitazoxanide significantly improved the resolution of diarrhoea, parasitological eradication, and mortality in HIV- seronegative, but not HIVseropositive,children. Rossignol JF, Ayoub A, Ayers MS. J Infect Dis. 2001 Jul 1;184(1):103-6.. Amadi B, Mwiya M, Musuku J, Watuka A, Sianongo S, Ayoub A, Kelly P. Lancet. 2002 2;360(9343):1375-80. In immunocompromised individuals there is no evidence for effective treatment (paromomycine and nitazoxanide) The most effective therapy in patients with AIDS is highly active antiretroviral treatment (HAART)© of by HIV. author Abubakar I, Aliyu SH, Arumugam C, Hunter PR, Usman NK. Cochrane Database Syst Rev. 2007 Jan 24;(1): Prevention and treatment of cryptosporidiosis in immunocompromised patients.. ESCMID Online Lecture Library Due to the seriousness of the potential outcomes of cryptosporidiosis, the use of nitaxozanide should be considered in immunocompromised patients Abubakar I, Aliyu SH, Arumugam C, Hunter PR, Usman NK. Cochrane Database Syst Rev. 2007 Jan 24;(1): Prevention and treatment of cryptosporidiosis in immunocompromised patients.. © by author ESCMID Online Lecture Library Additional techniques 4 diagnosis © by author of intestinal parasites ESCMID Online Lecture Library © by author ESCMID Online Lecture Library Quality control • External quality proficiency panels • Internal quality program – Internal standard – Other test eg G lamblia ELISA – Inter observer testing – Spot test © by author – QC fixatives – Prevalence rates in own population ESCMID Online Lecture Library © by author ESCMID Online Lecture Library Schistosomiasis • Glycerin sedimentation • Serology (time lag between possible exposition – testing minimal 8 weeks!) © by author ESCMID Online Lecture Library Strongyloides stercoralis Immunocompromised / transplantation • Baermann technique for rabditiform larvae – Hookworm!! genital premordium • Culture for filariform larvae – Hookworm: tapered© tail by Stongyloides: author forked tail • Serology (timelag!!) ESCMID Online Lecture Library High probability of helminth infection • eg refugees • Ridley concentration from all 3 fecal samples ( 2 SAF fixed, 1 fresh) © by author ESCMID Online Lecture Library Microsporidium • Profound diarrhoea in immunocompromised patient in particular HIV/AIDS (CD4 < 100) • Saline Ridley / no wooden sticks • Calcofluor staining • Trichrome acc weber • PCR © by author • Spores are very small ESCMID Online Lecture Library Non- morfological techniques • Copro ELISA • PCR © by author ESCMID Online Lecture Library Potential pro’s and cons • No specialized personnel in parasite morfology is needed anymore • Expensive training program • For ELISA every laboratory can do it • For PCR trained personnel and molecular facilities are mandatory © by author • Antigens and DNA are shedded continuously; so single sample testing is sufficient ESCMID Online Lecture Library Frequently found intestinal parasites in the Netherlands Protozoans Helminths Giardia lamblia Ascaris lumbricoides Entamoeba histolytica/dispar Enterobius vermicularis Cryptosporidium spp Hymenolepis nana Cyclospora cayetanensis Hymenolepis diminuta Dientamoeba fragilis Hookworm Cytoisospora belli Schistosoma spp Microsporidium spp Strongyloides stercoralis Trichuris trichiura Blastocystis hominis Taenia spp Endolimax nana Entamoeba hartmanni Entamoeba coli © by author Enteromonas hominis Iodamoeba bütschlii Chilomastix mesnili ESCMID Online Lecture Library Frequently found intestinal parasites in the Netherlands Protozoans Helminths Giardia lamblia Ascaris lumbricoides Entamoeba histolytica/dispar Enterobius vermicularis Cryptosporidium spp Hymenolepis nana Cyclospora cayetanensis Hymenolepis diminuta Dientamoeba fragilis Hookworm Cytoisospora belli Schistosoma spp Microsporidium spp Strongyloides stercoralis Trichuris trichiura Blastocystis hominis Taenia spp Endolimax nana Entamoeba hartmanni Entamoeba coli © by author Enteromonas hominis Iodamoeba bütschlii Chilomastix mesnili ESCMID Online Lecture Library Non- morfological techniques • Copro ELISA – Giardia / Crypto: from SAF and fresh – E. histolytica: only from fresh • Sens higher if performed from sediment after saline Ridley © by author • PCR – fresh stoolsample (day 2) ESCMID Online Lecture Library Sensitivity of the Triple-Faeces-Test (T.F.T.) versus Enzyme Immuno Assay in the laboratory diagnosis of Giardiasis © by author ESCMID Online Lecture Library Methods • Prospective study • TFT sets from routine clinical practice • Microscopy (AMC) • JKJ direct smear, Chlorazol Black stained smear formalin ether sedimentation according Ridley • EIA testing (Haarlem) • Three stool samples© by (day author 1, 2, and 3) in three EIA’s Prospect Giardia (Alexon, Remel), Techlab test Biotech Trinity test ESCMID Online Lecture Library Methods • Microscopy according to standardized protocol (magnification, time) • EIA observer blind • Discrepancy study © by author ESCMID Online Lecture Library Results T.F.T. sets (patients) included: 171 • Microscopy positive: 9 (5,3%) • Remel ProsPect Giardia positive: 10 (+1) • Giardia test Techlab positive: 26 (+19) • Giardia Trinity Biotech positive: 52 (+43) discrepancy study:© false by negativeauthor microscopy 1 x ESCMID Online Lecture Library Results of the microscopic examination of the TFT set of Giardia lamblia infected cases (N=9) Case day 1 day2 day3 1 - cysts - 2 - cysts - 3 cyst + trof cysts cyst + trof 4 cysts - - 5 cysts cysts - 6 - cysts cysts 7 - - cysts 8 - © bycyst authors cyst + trof 9 cysts cysts - ESCMID Online Lecture Library Results of the microscopic examination and EIA of the TFT set of Giardia lamblia infected cases (N=11) Case day 1 day2 day3 1 neg cysts neg 2 neg cysts neg 3 cysts + trof cysts cyst + trof 4 cysts neg neg 5 cysts cysts neg 6 neg cysts cysts 7 neg neg cysts 8 neg © bycyst authors cyst + trof 9 cysts cysts neg 10 neg neg neg 11 ESCMIDneg Online neg Lecture Libraryneg Testcharacteristics of the different diagnostic strategies compared with the yield of the ‘optimal test’ for laboratory diagnosis of giardiasis Diagnostic Strategy Optimal test false negatives sensitivity NPV (%) (%) microscopy day 1 7 36 95 microscopy day 2 4 64 97 microscopy day 3 7 36 96 TFT 2 82 99 Prospect day 1 © by4 author 64 98 Prospect day 2 3 73 98 Prospect day 3 3 73 98 ProspectESCMID TFT Online Lecture1 Library91 99 Conclusions Although to a lesser extent than cysts and trofozoites, the shedding of G. lamblia specific antigens is intermittent in patients infected with Giardia lamblia. The T.F.T. set has a higher sensitivity as compared to a “single EIA” The Remel (Alexon) ProsPect Giardia test is a powerful diagnostic tool in the laboratory diagnosis of giardiasis © by author ESCMID Online Lecture Library New developments / trends 1 New tests R-Biopharm – ridascreen ridascreen Cryptosporidium ridascreen Giardia lamblia Multi parasite testing Giardia + Cryptosporidium Make it easier © by author rapid test / dipstick ESCMID Online Lecture Library Name Firm Remarks Triage parasite Biosite Giardia lamblia Cryptosporidium spp E. histo/dispar X/pect Remel Giardia solo (Oxoid) Giardia / Crypto combi ImmunoCardSTAT Meridian Giardia lamblia © by authorCryptosporidium spp Rida Quick r-biopharm Giardia solo ESCMID Online(Bipharma) Lecture Giardia Library / Crypto combi © by author ESCMID
Load more

Recommended publications
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Giardiasis Importance Giardiasis, a Gastrointestinal Disease Characterized by Acute Or Chronic Diarrhea, Is Caused by Protozoan Parasites in the Genus Giardia
    Giardiasis Importance Giardiasis, a gastrointestinal disease characterized by acute or chronic diarrhea, is caused by protozoan parasites in the genus Giardia. Giardia duodenalis is the major Giardia Enteritis, species found in mammals, and the only species known to cause illness in humans. This Lambliasis, organism is carried in the intestinal tract of many animals and people, with clinical signs Beaver Fever developing in some individuals, but many others remaining asymptomatic. In addition to diarrhea, the presence of G. duodenalis can result in malabsorption; some studies have implicated this organism in decreased growth in some infected children and Last Updated: December 2012 possibly decreased productivity in young livestock. Outbreaks are occasionally reported in people, as the result of mass exposure to contaminated water or food, or direct contact with infected individuals (e.g., in child care centers). People are considered to be the most important reservoir hosts for human giardiasis. The predominant genetic types of G. duodenalis usually differ in humans and domesticated animals (livestock and pets), and zoonotic transmission is currently thought to be of minor significance in causing human illness. Nevertheless, there is evidence that certain isolates may sometimes be shared, and some genetic types of G. duodenalis (assemblages A and B) should be considered potentially zoonotic. Etiology The protozoan genus Giardia (Family Giardiidae, order Giardiida) contains at least six species that infect animals and/or humans. In most mammals, giardiasis is caused by Giardia duodenalis, which is also called G. intestinalis. Both names are in current use, although the validity of the name G. intestinalis depends on the interpretation of the International Code of Zoological Nomenclature.
    [Show full text]
  • Cas9-Mediated Genome Editing in Giardia Intestinalis
    bioRxiv preprint doi: https://doi.org/10.1101/2021.04.21.440745; this version posted April 21, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Cas9-mediated genome editing in Giardia intestinalis Vendula Horáčková1*, Luboš Voleman1*, Markéta Petrů1, Martina Vinopalová1, Filip Weisz2, Natalia Janowicz1, Lenka Marková1, Alžběta Motyčková1, Pavla Tůmová2, Pavel Doležal1 1Department of Parasitology, Faculty of Science, Charles University, BIOCEV, Průmyslová 595, Vestec 252 50, Czech Republic 2Institute of Immunology and Microbiology, First Faculty of Medicine and General University Hospital, Charles University in Prague, Czech Republic Abstract CRISPR/Cas9 system is an extremely powerful technique that is extensively used for different genome modifications in various organisms including parasitic protists. Giardia intestinalis, a protozoan parasite infecting large number of people around the world each year, has been eluding the use of CRISPR/Cas9 technique so far which may be caused by its rather complicated genome containing four copies of each gene in its two nuclei. Apart from only single exception (Ebneter et al., 2016), without the use of CRISPR/Cas9 technology in its full potential, researchers in the field have not been able to establish knock-out cell lines to study the functional aspect of Giardia genes. In this work, we show the ability of in-vitro developed CRISPR/Cas9 components to successfully edit the genome of G. intestinalis. Moreover, we used ‘self-propagating’ CRISPR/Cas9 system to establish full knock-out cell lines for mem, cwp1 and mlf1 genes. We also show that the system function even for essential genes, as we knocked-down tom40, lowering the amount of Tom40 protein by more than 90%.
    [Show full text]
  • The Intestinal Protozoa
    The Intestinal Protozoa A. Introduction 1. The Phylum Protozoa is classified into four major subdivisions according to the methods of locomotion and reproduction. a. The amoebae (Superclass Sarcodina, Class Rhizopodea move by means of pseudopodia and reproduce exclusively by asexual binary division. b. The flagellates (Superclass Mastigophora, Class Zoomasitgophorea) typically move by long, whiplike flagella and reproduce by binary fission. c. The ciliates (Subphylum Ciliophora, Class Ciliata) are propelled by rows of cilia that beat with a synchronized wavelike motion. d. The sporozoans (Subphylum Sporozoa) lack specialized organelles of motility but have a unique type of life cycle, alternating between sexual and asexual reproductive cycles (alternation of generations). e. Number of species - there are about 45,000 protozoan species; around 8000 are parasitic, and around 25 species are important to humans. 2. Diagnosis - must learn to differentiate between the harmless and the medically important. This is most often based upon the morphology of respective organisms. 3. Transmission - mostly person-to-person, via fecal-oral route; fecally contaminated food or water important (organisms remain viable for around 30 days in cool moist environment with few bacteria; other means of transmission include sexual, insects, animals (zoonoses). B. Structures 1. trophozoite - the motile vegetative stage; multiplies via binary fission; colonizes host. 2. cyst - the inactive, non-motile, infective stage; survives the environment due to the presence of a cyst wall. 3. nuclear structure - important in the identification of organisms and species differentiation. 4. diagnostic features a. size - helpful in identifying organisms; must have calibrated objectives on the microscope in order to measure accurately.
    [Show full text]
  • Intestinal Parasitic Infection Effect on Some Blood Components
    Research ISSN 2413-0516 Intestinal parasitic infection effect on some blood components Hanaa Daaj Khalaf Al-Mozan,a Yahya Tomaa Daoud,b Khalid Majeed Dakhilc aBiology Department, Science College, Thi-Qar University, Iraq. bBiology Department, Science for Women College, Baghdad University, Iraq. cTechnical Institute in Nassiriyah, Iraq. Correspondence to Hanaa Daaj Khalaf Al-Mozan (email: hanaa_daaj @yahoo.com). (Submitted: 14 December 2016 – Revised version received: 27 December 2016 – Accepted: 10 January 2017 – Published online: 26 March 2017) Objectives To know the effect of intestinal parasitic infection on the differential count of white blood cells and sex factor effect on some blood criteria. Methods The fecal samples were examined by direct and indirect methods. Blood samples were withdrawn for the testing of the differential count of white blood cells, Hb, PCV, T.WBC and numbers of eosinophils. Results The results showed that AL-Jibaish General Hospital was the highest with parasitic infection (50.4%) in comparison with other hospitals. A high percentage (30%) of Entamoeba histolytica was formed. When compared with the percentage of each parasite under study between those hospitals, Entamoeba histolytica appeared with 12% in AL-Shatra and 46.6% in AL-Jibaish. There were significant differences between the parasite types in the percent of lymphocytes, neutrophils, monocytes and eosinophils. It ranged from increase and decrease according to parasite type. The significant difference appeared at the six-factor effect on the number of eosinophils was calculated by using the statistical analysis (χ2) in level P < 0.05. Conclusion E. histolytica is the most common parasite. AL-Jibaish district suffers from a lack of services.
    [Show full text]
  • The Cytoskeleton of Giardia Lamblia
    International Journal for Parasitology 33 (2003) 3–28 www.parasitology-online.com Invited review The cytoskeleton of Giardia lamblia Heidi G. Elmendorfa,*, Scott C. Dawsonb, J. Michael McCafferyc aDepartment of Biology, Georgetown University, 348 Reiss Building 37th and O Sts. NW, Washington, DC 20057, USA bDepartment of Molecular and Cell Biology, University of California Berkeley, 345 LSA Building, Berkeley, CA 94720, USA cDepartment of Biology, Johns Hopkins University, Integrated Imaging Center, Baltimore, MD 21218, USA Received 18 July 2002; received in revised form 18 September 2002; accepted 19 September 2002 Abstract Giardia lamblia is a ubiquitous intestinal pathogen of mammals. Evolutionary studies have also defined it as a member of one of the earliest diverging eukaryotic lineages that we are able to cultivate and study in the laboratory. Despite early recognition of its striking structure resembling a half pear endowed with eight flagella and a unique ventral disk, a molecular understanding of the cytoskeleton of Giardia has been slow to emerge. Perhaps most importantly, although the association of Giardia with diarrhoeal disease has been known for several hundred years, little is known of the mechanism by which Giardia exacts such a toll on its host. What is clear, however, is that the flagella and disk are essential for parasite motility and attachment to host intestinal epithelial cells. Because peristaltic flow expels intestinal contents, attachment is necessary for parasites to remain in the small intestine and cause diarrhoea, underscoring the essential role of the cytoskeleton in virulence. This review presents current day knowledge of the cytoskeleton, focusing on its role in motility and attachment.
    [Show full text]
  • Nitroaromatic Antibiotics As Nitrogen Oxide Sources
    Review biomolecules Nitroaromatic Antibiotics as Nitrogen Oxide Sources Review Allison M. Rice, Yueming Long and S. Bruce King * Nitroaromatic Antibiotics as Nitrogen Oxide Sources Department of Chemistry and Biochemistry, Wake Forest University, Winston-Salem, NC 27101, USA; Allison M. Rice , Yueming [email protected] and S. Bruce (A.M.R.); King [email protected] * (Y.L.) * Correspondence: [email protected]; Tel.: +1-336-702-1954 Department of Chemistry and Biochemistry, Wake Forest University, Winston-Salem, NC 27101, USA; [email protected]: Nitroaromatic (A.M.R.); [email protected] antibiotics (Y.L.) show activity against anaerobic bacteria and parasites, finding * Correspondence: [email protected]; Tel.: +1-336-702-1954 use in the treatment of Heliobacter pylori infections, tuberculosis, trichomoniasis, human African trypanosomiasis, Chagas disease and leishmaniasis. Despite this activity and a clear need for the Abstract: Nitroaromatic antibiotics show activity against anaerobic bacteria and parasites, finding usedevelopment in the treatment of new of Heliobacter treatments pylori forinfections, these conditio tuberculosis,ns, the trichomoniasis, associated toxicity human Africanand lack of clear trypanosomiasis,mechanisms of action Chagas have disease limited and their leishmaniasis. therapeutic Despite development. this activity Nitroaro and a clearmatic need antibiotics for require thereductive development bioactivation of new treatments for activity for theseand this conditions, reductive the associatedmetabolism toxicity can convert
    [Show full text]
  • Elizabeth J. Walsh Professor - Biological Sciences University of Texas at El Paso December 10, 2019
    Elizabeth J. Walsh Professor - Biological Sciences University of Texas at El Paso December 10, 2019 1. Education B.S., Animal Biology, University of Nevada, Las Vegas, December 1983. Ph.D., Environmental Biology, University of Nevada, Las Vegas, Las Vegas, Nevada, May, 1992. Mentor: Dr. Peter L. Starkweather Dissertation title: Ecological and genetic aspects of the population biology of the littoral rotifer Euchlanis dilatata 2. Professional Employment - UTEP September 2014 to Director Ecology and Evolutionary Biology Program Present June 2013 to Interim Department Chair September 2014 September 2008 to Professor of Biological Sciences Present University of Texas at El Paso September 2000 to Associate Professor of Biological Sciences August 2008 University of Texas at El Paso September 1994 to Assistant Professor of Biological Sciences 2000 University of Texas at El Paso 3. Professional Employment – Prior to UTEP July 1993 to Postdoctoral Research Associate, September 1994 Department of Zoology, Brigham Young University September 1992- Lecturer, Rutgers University, December 1992 Population Ecology (Graduate level) December 1991- Gallagher Postdoctoral Fellow, June 1993 Academy of Natural Sciences of Philadelphia 4. Professional Societies American Microscopical Society, Executive Committee Member at Large of Board (2012-2014) Association for the Sciences of Limnology and Oceanography Ecological Society of America Society of Environmental Toxicology and Chemistry, Scientific Program Committee (2011-2012) Southwest Association of Naturalist Sigma Xi 5. Awards 1. UTEP Academy of Distinguished Teachers (April 2019) 1. University Faculty Marshals of Students (May 2019, December 2019) 2. Graduate School Faculty Marshal of Students (May 2017) 3. University of Texas Regents’ Outstanding Teaching Award (2015). UTEP nominee, (2014); College of Science (2012, 2013, 2014); Department of Biological Science (2012, 2013, 2014) 4.
    [Show full text]
  • Secnidazole (Solosec) Reference Number: CP.PMN.103 Effective Date: 03.01.18 Last Review Date: 02.20 Line of Business: Commercial, HIM, Medicaid Revision Log
    Clinical Policy: Secnidazole (Solosec) Reference Number: CP.PMN.103 Effective Date: 03.01.18 Last Review Date: 02.20 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Secnidazole (Solosec ™) is a 5-nitroimidazole antimicrobial. FDA Approved Indication(s) Solosec is indicated for the treatment of bacterial vaginosis in adult women. Limitation(s) of use: To reduce the development of drug-resistant bacteria and maintain the effectiveness of Solosec and other antibacterial drugs, Solosec should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Solosec is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Bacterial Vaginosis (must meet all): 1. Diagnosis of bacterial vaginosis; 2. Age ≥ 18 years; 3. Failure of both of the following agents (see Appendix B): metronidazole and clindamycin, with at least one of the agents used within the last 6 months, unless contraindicated or clinically significant adverse effects are experienced; 4. Dose does not exceed a single dose of 2 grams (1 packet). Approval duration: 7 days (1 packet total) B. Other diagnoses/indications 1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.
    [Show full text]
  • Original Article Hematological Profile in Natural Progression of Giardiasis: Kinetics of Experimental Infection in Gerbils
    Original Article Hematological profile in natural progression of giardiasis: kinetics of experimental infection in gerbils Frederico Ferreira Gil1, Luciana Laranjo Amorim Ventura1, Joice Freitas Fonseca1, Helton Costa Santiago2, Haendel Busatti3, Joseph Fabiano Guimarães Santos4; Maria Aparecida Gomes1 1 Departamento de Parasitologia, Instituto de Ciencias Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brasil 2 Departamento de Bioquímica, Instituto de Ciencias Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brasil 3 Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade de Itaúna, Itaúna, Brasil 4 Hospital Universitário Lucas Machado – FELUMA, Belo Horizonte, Brasil Abstract Introduction: The clinical manifestations of giardiasis and its impact are harmful to children, and may cause deficits in their physical and cognitive development. The pathogenic mechanisms are usually unknown and the available reports can be controversial. Methodology: The present study aimed to know, for the first time, the evolution of the hematological profile of the gerbils, experimentally infected with Giardia lamblia, up to the infection’s resolution. Hematological variables have been tested. Results: White blood cells have not presented meaningful alterations during the course of the infection. A significant reduction in the number of red blood cells (p = 0.021), in the concentration of hemoglobin (p = 0.029) and in the value of the hematocrit (p = 0.016) has been observed, starting from the second week of infection, ratifying an anemia related to giardiasis. Reduction in the level of serum iron starting from the third week of infection, despite not being significant, could suggest the participation of iron in the anemia. However, the weight of the animals was kept and the hematimetric parameters started to return to the basic values after the parasitological cure without iron reposition.
    [Show full text]
  • Molecular Diagnosis and Genotype Analysis of Giardia Duodenalis In
    Infection, Genetics and Evolution 32 (2015) 208–213 Contents lists available at ScienceDirect Infection, Genetics and Evolution journal homepage: www.elsevier.com/locate/meegid Molecular diagnosis and genotype analysis of Giardia duodenalis in asymptomatic children from a rural area in central Colombia ⇑ Juan David Ramírez a, , Rubén Darío Heredia b, Carolina Hernández a, Cielo M. León a, Ligia Inés Moncada b, Patricia Reyes b, Análida Elizabeth Pinilla c, Myriam Consuelo Lopez b a Grupo de Investigaciones Microbiológicas – UR (GIMUR), Facultad de Ciencias Naturales y Matemáticas, Universidad del Rosario, Bogotá, Colombia b Departamento de Salud Pública, Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, Colombia c Departamento de Medicina, Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, Colombia article info abstract Article history: Giardiasis is a parasitic infection that affects around 200 million people worldwide. This parasite presents Received 10 November 2014 a remarkable genetic variability observed in 8 genetic clusters named as ‘assemblages’ (A–H). These Received in revised form 9 March 2015 assemblages are host restricted and could be zoonotic where A and B infect humans and animals around Accepted 12 March 2015 the globe. The knowledge of the molecular epidemiology of human giardiasis in South-America is scarce Available online 18 March 2015 and also the usefulness of PCR to detect this pathogen in fecal samples remains controversial. The aim of this study was to conduct a cross-sectional study to compare the molecular targets employed for the Keywords: molecular diagnosis of Giardia DNA and to discriminate the parasite assemblages circulating in the stud- Molecular epidemiology ied population.
    [Show full text]
  • 204684Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 204684Orig1s000 MEDICAL REVIEW(S) Clinical Investigator Financial Disclosure Review Template Application Number: 204684 Submission Date(s): September 27, 2012 and April 19, 2013 Applicant: Paladin Therapeutics, Inc. Product: IMPAVIDO (miltefosine) Reviewer: Hala Shamsuddin, M.D. Date of Review: February 24, 2014 Covered Clinical Study (Name and/or Number): Study 3154 Study 3168 Study Z020a and b Study SOTO Study Z022 Dutch PK study Was a list of clinical investigators provided: Yes X No (Request list from applicant) Total number of investigators identified: Six (6) Number of investigators who are sponsor employees (including both full-time and part-time employees): None Number of investigators with disclosable financial interests/arrangements (Form FDA 3455): Six (6) If there are investigators with disclosable financial interests/arrangements, identify the number of investigators with interests/arrangements in each category (as defined in 21 CFR 54.2(a), (b), (c) and (f)): Compensation to the investigator for conducting the study where the value could be influenced by the outcome of the study: None Significant payments of other sorts: None Proprietary interest in the product tested held by investigator: None Significant equity interest held by investigator in sponsor of covered study: None Is an attachment provided with details Yes X No (Request details from of the disclosable financial applicant) interests/arrangements: Is a description of the steps taken to Yes X No (Request information minimize potential bias provided: from applicant) Number of investigators with certification of due diligence (Form FDA 3454, box 3) None Is an attachment provided with the NA No (Request explanation Reference ID: 3464181 reason: from applicant) Discuss whether the applicant has adequately disclosed financial interests/arrangements with clinical investigators as recommended in the guidance for industry Financial Disclosure by Clinical Investigators.
    [Show full text]